术前骨化三醇减少肾源性甲状旁腺功能亢进甲状旁腺次全切除术后静脉钙需求及住院时间
本研究回顾性比较了肾源性甲状旁腺功能亢进行甲状旁腺次全切除术患者术前接受骨化三醇治疗(41例)与未接受(40例)的差异。术前骨化三醇组术后静脉钙使用比例显著降低(34% vs 90%,P<.001),中位住院时间缩短2.0天(P<.001);多因素调整后术前骨化三醇仍独立关联减少术后静脉钙使用(OR 0.02,P<.001)。
要点
- 术前骨化三醇(0.5 mcg 每日两次×5天)可减少术后静脉钙使用。
- 术前骨化三醇组术后静脉钙使用率34%,未用组90%。
- 术前骨化三醇组中位住院时间缩短2.0天。
核心结论
- 术前骨化三醇治疗使肾源性甲状旁腺功能亢进甲状旁腺次全切除术后静脉钙使用减少56%、住院时间减少50%。
- 作者认为术前骨化三醇应成为该手术的标准治疗。
研究设计与样本
- 单中心回顾性病历对照研究,比较术前接受骨化三醇治疗与未接受治疗的患者。
- 共纳入81例因肾源性甲状旁腺功能亢进行甲状旁腺次全切除术的患者,其中41例接受术前骨化三醇,40例未接受。
- 术前骨化三醇负荷剂量为0.5 mcg每日两次,共5天。
- 所有患者术后均接受骨化三醇和口服碳酸钙。
- 术后静脉钙给予指征为出现症状、血钙<7.0 mg/dL或术者偏好。
主要发现
- 术前骨化三醇组术后静脉钙使用率为34%,未用组为90%(P<.001)。
- 术前骨化三醇组中位住院时间较未用组缩短2.0天(P<.001)。
- 与术后静脉钙使用相关的因素包括未接受术前骨化三醇、术前低钙和术前高甲状旁腺激素。
- 多因素调整后,术前骨化三醇仍独立关联减少术后静脉钙使用(OR 0.02,P<.001)。
- 术前骨化三醇使用率随时间增加:2004-2010年为0%,2011-2016年为69%。
关键数值与推荐
- 术前骨化三醇负荷方案:0.5 mcg每日两次,共5天。
- 术后静脉钙给予条件:有症状、血钙<7.0 mg/dL或术者偏好。
- 两组术前血清钙、维生素D、甲状旁腺激素及中位年龄相似(P>.05)。
临床怎么用
- 对拟行甲状旁腺次全切除术的肾源性甲状旁腺功能亢进患者,可考虑术前给予骨化三醇0.5 mcg每日两次共5天。
- 术前骨化三醇有望降低术后静脉钙需求并缩短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing subtotal parathyroidectomy for renal-origin hyperparathyroidism often develop postoperative hypocalcemia, requiring calcitriol and intravenous calcium (Postop-IVCa). We hypothesized that in subtotal parathyroidectomy for renal-origin hyperparathyroidism, preoperative calcitriol treatment reduces the use of postoperative administration of intravenous calcium. METHODS: A retrospective chart review compared subtotal parathyroidectomy for renal-origin hyperparathyroidism patients who received preoperative calcitriol treatment with those patietns who did not receive preoperative calcitriol treatment at one institution. Preoperative calcitriol treatment loading doses were 0.5 mcg twice daily for 5 days. All patients received postoperative calcitriol and oral calcium carbonate. Postoperative administration of intravenous calcium was given for symptoms, calcium <7.0 mg/dL, or surgeon preference. The Fisher exact test was used to compare proportions. The Wilcoxon test was used to compare continuous data. Multivariable logistic regression adjusted for confounders. RESULTS: Included were 81 patients who received subtotal parathyroidectomy for renal-origin hyperparathyroidism (41 patients who received preoperative calcitriol treatment, 40 patients who did not receive preoperative calcitriol treatment). Preoperative calcitriol treatment use increased over time (0% 2004-2010, 69% 2011-2016). Groups who received preoperative calcitriol treatment and groups who did not receive preoperative calcitriol treatment were similar in preoperative serum calcium, vitamin D, parathyroid hormone, and median age (P > .05 for all). Patients who received preoperative calcitriol treatment less often required postoperative administration of intravenous calcium (34% vs 90% of patients who did not receive preoperative calcitriol treatment, P < .001). Median length of stay was 2.0 days shorter for patients who received preoperative calcitriol treatment versus patients who did not receive preoperative calcitriol treatment patients (P < .001). Factors associated with postoperative administration of intravenous calcium included not receiving preoperative calcitriol treatment, low preoperative calcium, and high preoperative parathyroid hormone. After multivariable adjustment, preoperative calcitriol treatment remained independently associated with reduced postoperative administration of intravenous calcium (OR 0.02, P < .001). CONCLUSION: Preoperative calcitriol therapy lowered use of postoperative administration of intravenous calcium by 56% and length of stay by 50% in subtotal parathyroidectomy for renal-origin hyperparathyroidism patients. We believe preoperative calcitriol treatment should become standard of care for subtotal parathyroidectomy for renal-origin hyperparathyroidism.
引用
- Alsafran S, Sherman SK, Dahdaleh FS, et al. Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery. 2018. PMID: 30413326. doi:10.1016/j.surg.2018.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。